Neurocrine Sues Lupin, Teva to Block Copies of Ingrezza Drug

July 19, 2021, 3:37 PM

Neurocrine said Lupin’s and Teva’s proposed generic versions of the 40- and 80-milligram capsules of its flagship Ingrezza, used to treat tardive dyskinesia, infringe as many as 16 patents for the drug.

  • Neurocrine is seeking court orders blocking copies until the patents have expired, according to complaints filed Friday in federal court in Wilmington, Delaware
  • Tardive dyskinesia, a side effect of certain medications used to treat mental illness, may appear as repetitive involuntary movements of face, torso and other body parts
  • Neurocrine asserted 13 patents against both Teva and Lupin, and three additional patents against Lupin, complaints ...

To read the full article log in. To learn more about a subscription click here.